Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 13;44(2):55.
doi: 10.1007/s10555-025-10271-5.

Role of PLK4 inhibition in cancer therapy

Kishore Banik  1 , Thomas J Hayman  2
Affiliations
Review

Role of PLK4 inhibition in cancer therapy

Kishore Banik et al. Cancer Metastasis Rev. .

Abstract

Genomic instability is a hallmark of cancer and is associated with tumor progression and therapeutic resistance. Centrioles and centrosomes are a critical determinant of genomic stability. Polo-like kinase 4 (PLK4) is a serine-threonine kinase that plays a critical role in the regulation of centrosome duplication. PLK4 overexpression drives tumorigenesis and has been shown to be overexpressed in a wide variety of human tumors, where it is associated with more advanced disease and worse clinical outcomes. As such, there has been significant interest in pharmacologically targeting PLK4 using small-molecule inhibitors for therapeutic gain in multiple cancer types. In this review, we will discuss the functions of PLK4 in normal and oncogenic processes. We will further discuss the current state of PLK4 as a therapeutic target in cancer by reviewing the current literature on PLK4 inhibitors in both the preclinical and clinical space. Finally, we will discuss the emerging data exploring rational combinations of PLK4 inhibitors with DNA-damaging agents and immunotherapies as a means to unlock the potential of these agents in cancer therapy.

Keywords: Cancer; Centrosome amplification; DNA-damaging therapy; PLK4; PLK4 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests.

References

    1. Chan, A. S., et al. (2014). Tumour suppressors and cellular senescence. IUBMB Life, 66(12), 812–822. - PubMed - DOI
    1. Abdel-Rahman, W. M. (2008). Genomic instability and carcinogenesis: An update. Current Genomics, 9(8), 535–541. - PubMed - PMC - DOI
    1. Andor, N., Maley, C. C., & Ji, H. P. (2017). Genomic instability in cancer: Teetering on the limit of tolerance. Cancer Research, 77(9), 2179–2185. - PubMed - PMC - DOI
    1. Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability–An evolving hallmark of cancer. Nature Reviews Molecular Cell Biology, 11(3), 220–228. - PubMed - DOI
    1. Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997). Genetic instability in colorectal cancers. Nature, 386(6625), 623–627. - PubMed - DOI

MeSH terms

Substances

LinkOut - more resources